Article Versions Notes

Fedele P, Landriscina M, Moraca L, Cusmai A, Gnoni A, Licchetta A, Lanotte L, Pappagallo MN, Melaccio A, Giordano G, et al. CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study. Cancers. 2025; 17(20):3302. https://doi.org/10.3390/cancers17203302

Fedele, Palma, Matteo Landriscina, Lucia Moraca, Antonio Cusmai, Antonio Gnoni, Antonella Licchetta, Laura Lanotte, Maria Nicla Pappagallo, Assunta Melaccio, Guido Giordano, and et al. 2025. "CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study" Cancers 17, no. 20: 3302. https://doi.org/10.3390/cancers17203302

Fedele, P., Landriscina, M., Moraca, L., Cusmai, A., Gnoni, A., Licchetta, A., Lanotte, L., Pappagallo, M. N., Melaccio, A., Giordano, G., Maselli, F. M., Giuliani, F., Chiuri, V., Giotta, F., Fumai, F., & Gadaleta-Caldarola, G. (2025). CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study. Cancers, 17(20), 3302. https://doi.org/10.3390/cancers17203302